We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

28 hedge funds and large institutions have $11.5M invested in Protalix BioTherapeutics in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

32% more capital invested

Capital invested by funds: $8.72M → $11.5M (+$2.77M)

1.28% less ownership

Funds ownership: 1.96% → 0.68% (-1.3%)

15% less funds holding

Funds holding: 33 → 28 (-5)

25% less call options, than puts

Call options by funds: $261K | Put options by funds: $348K

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
28
Holders Change
-5
Holders Change %
-15.15%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
5
Closed
12
Calls
$261K
Puts
$348K
Net Calls
-$87K
Net Calls Change
-$87K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.3M
2
ARTA
A.R.T. Advisors
New York
+$193K
3
Simplex Trading
Simplex Trading
Illinois
+$115K
4
WAM
Wolverine Asset Management
Illinois
+$94.4K
5
BlackRock
BlackRock
New York
+$92K

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$4.3M
2
IAM
Ion Asset Management
Israel
-$2.21M
3
UOC
UBS O'Connor
Illinois
-$1.78M
4
AGC
Angelo Gordon & Co
New York
-$470K
5
Citigroup
Citigroup
New York
-$260K
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.4K +$2.25K +250 New
Manulife (Manufacturers Life Insurance)
27
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
UBS Group
28
UBS Group
Switzerland
$1K – – –
HCM
29
Highbridge Capital Management
New York
– -$4.3M -477,980 Closed
UOC
30
UBS O'Connor
Illinois
– -$1.78M -400,000 Closed
AGC
31
Angelo Gordon & Co
New York
– -$470K -105,707 Closed
Citigroup
32
Citigroup
New York
– -$260K -58,479 Closed
Parallax Volatility Advisers
33
Parallax Volatility Advisers
California
– -$127K -14,152 Closed
Millennium Management
34
Millennium Management
New York
– -$49K -11,010 Closed
Goldman Sachs
35
Goldman Sachs
New York
– -$18K -4,062 Closed
SIM
36
Spark Investment Management
New York
– -$10K -2,380 Closed
NCCM
37
Nine Chapters Capital Management
New Jersey
– -$9K -2,130 Closed
WS
38
Wedbush Securities
California
– -$8K -1,800 Closed
VKH
39
Virtu KCG Holdings
New York
– -$5K -1,121 Closed
PCM
40
Prelude Capital Management
New York
– -$5K -1,050 Closed
1
2

PLX Hedge Fund Activity: Q1 2017 in Review

28 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2017, worth a combined $11.5M — up 32% from $8.72M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PLX and 8 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 9 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.3M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $4.3M sold.

  • 28 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2017, down from 33 in Q4 2016.
  • Funds reported $11.5M of Protalix BioTherapeutics stock for Q1 2017, up 32% quarter-over-quarter.
  • 8 funds opened new Protalix BioTherapeutics positions in Q1 2017 and 12 closed out, a net change of -4 holders.
  • The largest Protalix BioTherapeutics buyer in Q1 2017 was Renaissance Technologies, an estimated $1.3M added.
  • The largest Protalix BioTherapeutics seller in Q1 2017 was Highbridge Capital Management, an estimated $4.3M sold.

Based on aggregated 13F filings for Q1 2017.